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Summary
Hundreds, if not thousands, of uncharacterized en-
zymes currently populate the human proteome.
Assembly of these proteins into themetabolic and sig-
naling pathways that govern cell physiology and pa-
thology constitutes a grand experimental challenge.
Here, we address this problem by using a multidimen-
sional profiling strategy that combines activity-based
proteomics and metabolomics. This approach deter-
mined that KIAA1363, an uncharacterized enzyme
highly elevated in aggressive cancer cells, serves
as a central node in an ether lipid signaling network
that bridges platelet-activating factor and lysophos-
phatidic acid. Biochemical studies confirmed that
KIAA1363 regulates this pathway by hydrolyzing the
metabolic intermediate 2-acetyl monoalkylglycerol. In-
activation of KIAA1363 disrupted ether lipid metabo-
lism in cancer cells and impaired cell migration and
tumor growth in vivo. The integrated molecular profil-
ingmethod described herein should facilitate the func-
tional annotation of metabolic enzymes in any living
system.
Introduction
Elucidation of the metabolic and signaling networks that
regulate health and disease stands as a principal goal
of postgenomic research. The remarkable complexity
of these molecular pathways has inspired the advance-
ment of ‘‘systems biology’’ methods for their character-
ization [1]. Toward this end, global profiling technologies,
such as DNA microarrays [2, 3] and mass spectrometry
(MS)-based proteomics [4, 5], have succeeded in gener-
ating gene and protein signatures that depict key fea-
tures of many human diseases. However, extricating
from these associative relationships the roles that spe-
cific biomolecules play in cell physiology and pathology
remains problematic, especially for proteins of unknown
biochemical or cellular function.
The functions of certain proteins, such as adaptor or
scaffolding proteins, can be gleaned from large-scale
protein-interaction maps generated by technologies
like yeast two-hybrid [6, 7], protein microarrays [8], and
MS analysis of immunoprecipitated protein complexes
[9, 10]. In contrast, enzymes contribute to biological pro-
cesses principally through catalysis. Thus, elucidation
*Correspondence: cravatt@scripps.edu
2 These authors contributed equally to this work.of the activities of the many thousands of enzymes en-
coded by eukaryotic and prokaryotic genomes requires
knowledge of their endogenous substrates and prod-
ucts. The functional annotation of enzymes in prokary-
otic systems has been facilitated by the clever analysis
of gene clusters or operons [11, 12], which correspond
to sets of genes adjacently located in the genome that
encode for enzymes participating in the same metabolic
cascade. The assembly of eukaryotic enzymes into met-
abolic pathways is more problematic, however, as their
corresponding genes are not, in general, physically orga-
nized into operons, but rather are scattered randomly
throughout the genome.
Given the absence of a functional architecture con-
necting eukaryotic genomes and proteomes, the activi-
ties of their enzyme constituents are typically assessed
in an empirical manner in vitro by using candidate sub-
strates and purified preparations of protein. The out-
come of these ‘‘test-tube’’ biochemistry studies can be
difficult to translate into a clear understanding of the
roles that enzymes play in living systems, where these
proteins are subjected to posttranslational regulation
[13] and typically operate as parts of larger metabolic
networks [14]. We hypothesized that the determination
of endogenous catalytic activities for uncharacterized
enzymes could be accomplished directly in living sys-
tems by the integrated application of global profiling
technologies that survey both the enzymatic proteome
and its primary biochemical output (i.e., the metabo-
lome). Here, we have tested this premise by utilizing
multidimensional profiling to characterize an integral
membrane enzyme of unknown function that is highly
elevated in human cancer.
Results
Development of a Selective Inhibitor for the
Uncharacterized Enzyme KIAA1363
Previous studies using the chemical proteomic technol-
ogy activity-based protein profiling (ABPP) [15–17] have
identified enzyme activity signatures that distinguish
human cancer cells based on their biological properties,
including tumor of origin and state of invasiveness [18].
A primary component of these signatures was the pro-
tein KIAA1363, an uncharacterized integral membrane
hydrolase found to be upregulated in aggressive cancer
cells from multiple tissues of origin. Since that time, the
mouse ortholog of KIAA1363 has been found to repre-
sent a major site of labeling for organophosphorus nerve
agents in brain tissue [19]; however, the endogenous
metabolic function(s) of this enzyme in mammalian
physiology and pathology remains unknown. To investi-
gate the role that KIAA1363 plays in cancer cell metabo-
lism and signaling, a selective inhibitor of this enzyme
was generated by competitive ABPP [20, 21].
Key advantages of competitive ABPP include that
it can be performed in native proteomes and used to
identify inhibitors for enzymes that, like KIAA1363, lack
known substrates. Moreover, because inhibitors are
screened against many enzymes in parallel, both
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1042Figure 1. Characterization of AS115, a Selec-
tive Inhibitor of the Cancer-Related Enzyme
KIAA1363
(A) Structure of AS115.
(B) Effects of AS115 on the membrane (left
image) and soluble (right image) serine
hydrolase activity profiles of SKOV-3 cells,
as judged by competitive ABPP with a rhoda-
mine-tagged FP probe [20]. In-gel fluores-
cence scanning of FP-labeled proteomes
derived from SKOV-3 cells treated in culture
with AS115 (0–10 mM) revealed selective
inactivation of KIAA1363 (red box). Note
that KIAA1363 migrates by SDS-PAGE as
a 43 and 45 kDa glycosylated doublet,
which, upon treatment with PNGaseF, is
converted into a single 40 kDa protein. This
protein is predominantly found in the mem-
brane fraction of cancer cells (left image).
(C) AS115 inhibited the FP labeling of
KIAA1363 with an IC50 value of 150 nM
(110–200 nM, 95% confidence limits; red
curve), while other serine hydrolases were
not affected by this reagent (IC50 values >
10 mM, representative hydrolases shown in
black curves corresponding to the double-
arrowed proteins in [B]). Results represent
the average values 6 standard error (SE)
for three independent experiments.potency and selectivity factors are simultaneously
assigned. Previous competitive ABPP screens with a
library of candidate inhibitors and a fluorophosphonate
(FP) activity-based probe that targets the serine hydro-
lase superfamily identified a set of trifluoromethyl ke-
tone (TFMK) inhibitors that showed activity against the
mouse ortholog of KIAA1363 in brain extracts [20].
These TFMK inhibitors also inhibited human KIAA1363
in vitro, but they showed only limited activity in living
cells (data not shown). We postulated that the in situ
activity of KIAA1363 inhibitors could be enhanced by
replacing the reversibly binding TFMK group with
a carbamate, which inactivates serine hydrolases via
a covalent mechanism (Figure S1; see the Supplemental
Data available with this article online). Carbamate
AS115 (Figure 1A) was synthesized and tested for its
effects on the invasive ovarian cancer cell line SKOV-3
by competitive ABPP (Figure 1B). AS115 was found to
potently and selectively inactivate KIAA1363, dis-
playing an IC50 value of 150 nM, while other serine hy-
drolase activities were not affected by this agent (IC50
values > 10 mM) (Figures 1B and 1C). AS115 also
selectively inhibited KIAA1363 in other aggressive can-
cer cell lines that possess high levels of this enzyme,
including the melanoma lines C8161 and MUM-2B
(Figure S2B).Profiling the Metabolic Effects of KIAA1363
Inactivation in Cancer Cells
We next compared the global metabolite profiles of
SKOV-3 cells treated with AS115 or vehicle (DMSO)
to identify endogenous small molecules regulated by
KIAA1363. These experiments were performed by using
a recently described, untargeted liquid chromatogra-
phy-mass spectrometry (LC-MS) platform for compara-
tive metabolomics [22]. AS115 (10 mM, 4 hr) was found
to cause a dramatic reduction in the levels of a specific
set of lipophilic metabolites (m/z 317, 343, and 345) in
SKOV-3 cells (Figure 2A). These KIAA1363-regulated
metabolites did not correspond to any of the typical lipid
species found in cells, including free fatty acids, phos-
pholipids, ceramides, and monoacylglycerides, none
of which were significantly altered by AS115 treatment
(Table S1). High-resolution MS of the m/z 317 metabolite
provided a molecular formula of C19H40O3 (Figure 2B),
which suggests that this compound might represent
a monoalkylglycerol ether bearing a C16:0 alkyl chain
(C16:0 MAGE). This structure assignment was corrobo-
rated by tandem MS and LC analysis, in which the en-
dogenous m/z 317 product and synthetic C16:0 MAGE
displayed equivalent fragmentation and migration pat-
terns, respectively (Figure S3). By extension, the m/z
343 and 345 metabolites were interpreted to represent
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LC-MS analysis with a 13C-MAGE internal standard
provided estimates of the absolute levels of MAGEs in
SKOV-3 cells, revealing that the C16:0 species was the
most abundant member of this lipid family (Table S2).
MAGE lipids were also significantly reduced in C8161
and MUM-2B melanoma cells after treatment with
AS115 (Figure S4). In contrast, a control carbamate in-
hibitor, URB597, which targets other hydrolytic enzymes
[23], but not KIAA1363, did not affect MAGE levels in
cancer cells (Figure S4).
Biochemical Characterization of KIAA1363
as a 2-Acetyl MAGE Hydrolase
The correlation between KIAA1363 inactivation and re-
duced MAGE levels suggests that these lipids are prod-
ucts of a KIAA1363-catalyzed reaction. A primary route
for the biosynthesis of MAGEs has been proposed to oc-
cur via the enzymatic hydrolysis of their 2-acetyl precur-
sors [24, 25]. This 2-acetyl MAGE hydrolysis activity was
first detected in cancer cell extracts over a decade ago
[25], but, to date, it has eluded molecular characteriza-
tion. To test whether KIAA1363 functions as a 2-acetyl
MAGE hydrolase, this enzyme was transiently trans-
Figure 2. Pharmacological Inhibition of KIAA1363 Reduces Mono-
alkylglycerol Ether, MAGE, Levels in Human Cancer Cells
(A) Global metabolite profiling of AS115-treated SKOV-3 cells (10 mM
AS115, 4 hr) with untargeted LC-MS methods [22] revealed a specific
reduction in a set of structurally related metabolites with m/z values
of 317, 343, and 345 (p < 0.001 for AS115- versus DMSO-treated
SKOV-3 cells). Results represent the average fold change for three
independent experiments. See Table S1 for a more complete list of
metabolite levels.
(B) High-resolution MS analysis of the sodium adduct of the purified
m/z317 metabolite provided a molecular formula of C19H40O3, which,
in combination with tandem MS and LC analysis (Figure S3), led to
the determination of the structure of this small molecule as C16:0
monoalkylglycerol ether (C16:0 MAGE).fected into COS7 cells. KIAA1363-transfected cells pos-
sessed significantly higher 2-acetyl MAGE hydrolase
activity compared to mock-transfected cells, and this
elevated activity was blocked by treatment with AS115
(Figure 3A). In contrast, KIAA1363- and mock-trans-
fected cells showed no differences in their respective
hydrolytic activity for 2-oleoyl MAGE, monoacylglycer-
ols, or phospholipids (e.g., platelet-activating factor
[PAF], phosphatidylcholine) (Figure S5A). These data
indicate that KIAA1363 selectively catalyzes the hydro-
lysis of 2-acetyl MAGEs to MAGEs.
Further biochemical studies indicated that KIAA1363
is the principal 2-acetyl MAGE hydrolase in cancer cells.
First, 2-acetyl MAGE hydrolase activity, like that of
KIAA1363, was predominantly associated with SKOV-3
membranes (Figure S5B). Additionally, fractionation of
the SKOV-3 membrane proteome by Q chromatography
revealed a tight relationship between KIAA1363 levels
and 2-acetyl MAGE hydrolase activity (Figure S5C).
Third, SKOV-3 cells possessed much greater 2-acetyl
MAGE hydrolase activity compared to the noninvasive
ovarian cancer line OVCAR-3 (Figure 3B), correlating
well with their respective levels of KIAA1363 (Figure 3C).
KIAA1363 Regulates an Ether Lipid Signaling
Network that Bridges Platelet-Activating
Factor and the Lysophospholipids
Examination of the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database [26] suggests that the
KIAA1363-MAGE pathway might serve as a unique met-
abolic node linking the PAF [27] and lysophospholipid
[28] signaling systems in cancer cells (Figure 4A). To
test this premise, the major components of this small-
molecule network were measured by targeted LC-MS
analysis in AS115- and vehicle-treated SKOV-3 cells.
AS115 was found to reduce the levels of not only
MAGEs, but also alkyl-LPC and alkyl-LPA (Figure 4B).
Consistent with a direct pathway leading from MAGEs
to these lysophospholipids, addition of 13C-MAGE to
SKOV-3 cells resulted in the formation of 13C-labeled
alkyl-LPC and alkyl-LPA (Figure 4C). Conversely, the
levels of 2-acetyl MAGE in SKOV-3 cells, as judged by
metabolic labeling experiments, were significantly sta-
bilized by treatment with AS115, which, in turn, led to
an accumulation of PAF (Figure 4D). Basal levels of 2-
acetyl MAGE and PAF were not significantly altered
by AS115, which may be related to the relatively short
duration of action of this inhibitor or to the regulation
of endogenous levels of these lipids by alternative rate-
limiting enzymatic pathways. Finally, a comparison of
the metabolite profiles of SKOV-3 and OVCAR-3 cells
revealed significantly higher levels of MAGE, alkyl-LPC,
and alkyl-LPA in the former line (Figure 4E). These data
indicate that the lysophospholipid branch of the MAGE
network is elevated in aggressive cancer cells, and that
this metabolic shift is regulated by KIAA1363.
Stable Knockdown of KIAA1363 Impairs
Tumor Growth In Vivo
We next asked whether KIAA1363 contributes to cancer
pathogenesis in vivo. This question could not be directly
addressed by using the KIAA1363 inhibitor AS115
because this agent lacked the pharmacokinetic proper-
ties suitable for long-term treatments in vivo (data not
Chemistry & Biology
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Hydrolase
(A) COS7 cells transiently transfected with a
KIAA1363 cDNA in the pcDNA3 expression
vector showed significantly greater 2-acetyl
MAGE hydrolase activity compared to
mock-transfected cells (transfected with
empty pcDNA3 vector). Pretreatment with
AS115 (10 mM) blocked the hydrolytic activity
of KIAA1363-transfected cells. **, p < 0.01 for
KIAA1363-transfected cells versus mock-
transfected or AS115-treated cells.
(B and C) (B) The invasive ovarian cancer line
SKOV-3 possessed significantly higher 2-
acetyl MAGE hydrolase activity compared to the noninvasive ovarian cancer line OVCAR-3, which correlated well with the respective levels
of KIAA1363 in these cells, as judged by ABPP ([C], upper panel) or western blotting with anti-KIAA1363 antibodies ([C], lower panel).
**, p < 0.01 for SKOV-3 cells versus OVCAR-3 cells or AS115-treated cells. Results represent the average values 6 SE for 3–6 independent
experiments.shown). Therefore, we generated a SKOV-3 line in which
the expression of KIAA1363 was selectively and stably
decreased by a short-hairpin RNA (shRNA)-mediated
interference vector (shKIAA1363 cells). An additional
control line (shControl) in which a distinct hydrolytic en-
zyme (dipeptidylpeptidase IV [DPPIV]) was knocked
down by a specific shRNA probe was also generated.
shKIAA1363 cells showed an w75% reduction of this
enzyme compared to control cells (shControl or parental
SKOV-3 cells) (Figure 5A), which correlated with a similar
magnitude decrease in 2-acetyl MAGE hydrolase activ-
ity (Figure 5B) and the levels of MAGE, alkyl-LPC, and
alkyl-LPA lipids (Figure 5C). The levels of other hydro-
lytic enzymes were not affected in shKIAA1363 cells,
as judged by gel-based ABPP (Figure S6).
shKIAA1363 and control SKOV-3 cells were next com-
pared for their tumor growth capacity by subcutaneous
injection into immune-deficient mice. shKIAA1363
SKOV-3 cells exhibited significantly reduced tumor
growth rates compared to either shControl cells or the
parental SKOV-3 line (Figure 6A). shRNA-mediated
knockdown of KIAA1363 was also performed in the ag-
gressive breast cancer line MDA-MB-231, resulting in
lowered MAGE and lysophosopholipid levels in these
cells and impaired tumor growth in vivo (Figure S7).
The decrease in tumorigenic potential of shKIAA1363
cells was not associated with a change in proliferation
potential in vitro (Figure S8). shKIAA1363 cells were,
however, impaired in their in vitro migration capacity
compared to control cells (Figure 6B). To discern whether
any of the lipids regulated by KIAA1363 might contribute
to cancer cell migration, we tested the pharmacological
effects of these compounds on shKIAA1363 cells. Nei-
ther MAGE nor alkyl-LPC impacted cancer cell migration
at concentrations up to 1 mM (Figure 6B). In contrast,
alkyl-LPA (10 nM) completely rescued the reduced mi-
gratory activity of shKIAA1363 cells. Collectively, these
results indicate that KIAA1363 contributes to the patho-
genic properties of cancer cells in vitro and in vivo,
possibly through regulating the levels of the bioactive
lipid LPA.
Discussion
We have determined by integrated enzyme and small-
molecule profiling that KIAA1363, a protein of previously
unknown function, is a 2-acetyl MAGE hydrolase thatserves as a key regulator of a lipid signaling network
that contributes to cancer pathogenesis. Although we
cannot yet conclude which of the specific metabolites
regulated by KIAA1363 supports tumor growth in vivo,
the rescue of the reduced migratory phenotype of
shKIAA1363 cancer cells by LPA is consistent with pre-
vious reports showing that this lipid signals through
a family of G protein-coupled receptors to promote can-
cer cell migration and invasion [28–30]. LPA is also an
established biomarker in ovarian cancer, and the levels
of this metabolite are elevated nearly 10-fold in ascites
fluid and plasma of patients with ovarian cancer [31].
Our results suggest that additional components in the
KIAA1363-ether lipid network, including MAGE, alkyl
LPC, and KIAA1363 itself, might also merit consideration
as potential diagnostic markers for ovarian cancer. Con-
sistent with this premise, our preliminary analyses have
revealed highly elevated levels of KIAA1363 in primary
human ovarian tumors compared to normal ovarian
tissues (data not shown). The heightened expression
of KIAA1363 in several other cancers, including breast
[18, 32], melanoma [18], and pancreatic cancer [33], indi-
cates that alterations in the KIAA1363-ether lipid net-
work may be a conserved feature of tumorigenesis.
Considering further that reductions in KIAA1363 activity
were found to impair tumor growth of both ovarian and
breast cancer cells, it is possible that inhibitors of this
enzyme may prove to be of value for the treatment of
multiple types of cancer.
Looking forward, it is worth discussing the potential
generality of the multidimensional profiling strategy
put forth in this study for the functional annotation of
other uncharacterized enzymes in eukaryotic and pro-
karyotic proteomes. The development of a selective in-
hibitor to perturb KIAA1363 function was predicated
on the availability of an activity-based proteomics probe
for this enzyme. Such probes are now available for many
enzyme classes that participate in cell metabolism,
including all major families of hydrolases [15], [34–39],
glycosidases [40, 41], kinases [42, 43], glutathione S-
transferases [44, 45], and oxidoreductases [45, 46], sug-
gesting that a large swath of the enzyme proteome could
be addressed by following the experimental strategy
presented herein. For enzymes that lack cognate activ-
ity-based probes, RNA interference (RNAi) methods,
coupled with metabolic profiling, may suffice for their
functional annotation. Indeed, if one takes KIAA1363
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1045Figure 4. KIAA1363 Serves as a Key Enzymatic Node in a Metabolic Network that Connects the PAF and Lysophospholipid Families of
Signaling Lipids
(A) Network diagram showing metabolite and enzyme components (metabolites are shown with a C16:0 alkyl chain for clarity of presentation).
(B) Treatment of SKOV-3 cells with AS115 (10 mM, 4 hr) reduced multiple components of the metabolite network, including MAGE, alkyl-LPC,
and alkyl-LPA. **, p < 0.01 for AS115- (white bars) versus DMSO- (black bars) treated SKOV-3 cells.
(C) Metabolic labeling of SKOV-3 cells with 13C-MAGE (10 mM, 4 hr) shows that this lipid can be directly converted to LPC and LPA. Data are
normalized to show relative MS signals for each lipid and its 13C variant. No accumulation of 13C-2-acetyl MAGE or 13C-PAF was observed after
treatment with 13C-MAGE.
(D) SKOV-3 cells treated with AS115 (white bar; 10 mM AS115, 0.5 hr) exhibited significantly reduced degradation of 13C-2-acetyl MAGE (10 mM,
1 hr) compared to DMSO-treated control cells (black bar). Accumulation of 13C-PAF was also observed in AS115-treated cells. **, p < 0.01 for
AS115- versus DMSO-treated SKOV-3 cells.
(E) MAGE and lysophospholipids (LPC and LPA) are highly elevated in SKOV-3 cells (black bars) compared to OVCAR-3 cells (white bars).
**, p < 0.01 for SKOV-3 versus OVCAR-3 cells. Results represent the average values 6 SE for 3–6 independent experiments.as a case study, the metabolic effects of perturbing this
enzyme by a small-molecule inhibitor or RNAi proved
complementary. The former approach allowed for visu-
alization of the acute effects of KIAA1363 inactivation,
facilitating the discovery of direct products (MAGEs) of
this enzyme. The constitutive disruption of KIAA1363
function by RNAi produced more dramatic network-
wide changes that impacted not only the direct, but
also downstream, metabolites (e.g., lysophospholipids)regulated by this enzyme. These findings suggest that
sole reliance on RNAi should enable the discovery of di-
rect products of enzymes in living systems, although the
identification of these molecules may require follow-up
biochemical assays to distinguish them from secondary
metabolites in enzyme-regulated networks.
Independent of the experimental strategy employed
for enzyme inactivation, a primary advantage of metab-
olite profiling in native biological systems is that it
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(A) SKOV-3 cells possessing a stably integrated shRNA specific for KIAA1363 showed anw75% reduction of this enzyme activity compared to
parental SKOV-3 cells or cells possessing a control shRNA that targeted the unrelated serine hydrolase DPPIV (shControl), as judged by ABPP.
The levels of other serine hydrolases were not affected in shKIAA1363 cells (Figure S6).
(B and C) shKIAA1363 SKOV-3 cells displayed significant reductions in (B) 2-acetyl MAGE hydrolase activity and (C) MAGE, alkyl-LPC, and
alkyl-LPA levels compared to control cells. ** p < 0.01, for shKIAA1363 (white bars) versus control cells (parental SKOV-3 [black] or shControl
[gray]). Results represent the average values 6 SE for six independent experiments.circumvents some of the most laborious and time-con-
suming steps that accompany the in vitro analysis of en-
zymes (i.e., recombinant expression and purification,
candidate substrate screening), and, at the same time,
generates data sets that are more directly related to their
endogenous activities. Expanded systems biology ef-
forts to assemble the full complement of enzymes
encoded by the human genome into metabolic and sig-
naling networks that contribute to complex pathologies,
like cancer, should lead to the discovery of many
new markers and targets for disease diagnosis and
treatment.
Figure 6. KIAA1363 Contributes to Ovarian Tumor Growth and
Cancer Cell Migration
(A) shKIAA1363 SKOV-3 cells showed significantly impaired tumor
growth rates in immune-deficient mice compared to control cells.
**, p < 0.01 for shKIAA1363 versus control cells. n = 7–10 mice
per group.
(B) shKIAA1363 SKOV-3 cells show reduced migration in vitro com-
pared to control cells. The reduced migration of shKIAA1363 cells
is reversed by treatment with C16:0-alkyl-LPA (10 nM), but not
C16:0-MAGE or C16:0-alkyl LPC (each tested from 10 nM to
1 mM; data shown for 100 nM). ** p < 0.01, for shKIAA1363 versus
control cells or shKIAA1363 cells treated with LPA. Results repre-
sent the average values 6 SE for 3–4 independent experiments.Significance
The complete genome sequences of several eukary-
otic and prokaryotic organisms have revealed a daunt-
ing number of uncharacterized proteins in need of
functional annotation. For enzymes, in particular, the
elucidation of endogenous substrates and products
is imperative for integrating these proteins into the
biochemical networks that govern health and disease.
Here, we present a multidimensional systems biology
strategy that addresses this problem. By combining
activity-based proteomic and metabolomic methods,
we have determined that the uncharacterized integral
membrane enzymeKIAA1363, which is highly elevated
in human cancer, serves as a critical node in an ether
lipid signaling network that links platelet-activating
factor and the lysophospholipids. Disruption of this
small-molecule network through the impairment of
KIAA1363 activity reduced cancer cell migration and
tumor growth in vivo, promoting this enzyme as a po-
tential therapeutic target for the treatment of cancer.
More generally, these results showcase the value of
integrated molecular profiling as an experimental




C17:0 lysophosphatidic acid (LPA), C16:0 2-acetyl MAGE, PAF, and
phosphtidylcholine were purchased from Avanti Lipids. C15:0
monoacylglycerol (MAG) was purchased from Larodan (Sweden).
FP-rhodamine was synthesized by following previously described
procedures [47, 48]. Synthesis of 13C-C16:0 MAGE was carried out
as described previously [49], and targeted acetylation to generate
13C-C16:0 2-acetyl MAGE was performed as reported [50]. The
synthesis of AS115 is detailed in Supplemental Data.
Plasmids
Human KIAA1363 construct was generated by PCR with primers 50-
CGCGGATCCATGAGGTCGTCCTGTGTCCTG-30 and 50-CGGAATT
CTTACAGGTTTTGATCTAGCC-30. PCR products were subcloned
into the pcDNA3.1+ vector (Invitrogen) by using BamHI and EcoRI
restriction sites.
In Situ Inhibition of KIAA1363 in Cancer Cells
The human ovarian cancer cell line were obtained form the National
Cancer Institute’s Developmental Therapeutics Program. The mela-
noma lines C8161 and MUM-2B were obtained from Mary Hendrix.
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serum at 37C in a humidified atmosphere of 5% CO2/95% air. At
w80% confluency, cells were trypsinized and counted with the aid
of a hemocytometer, and 2.53 106 cells were plated in 6 cm dishes.
A total of 20 hr after plating, cells were washed twice with PBS and
supplemented with serum-free RPMI containing 0.5% BSA (Sigma)
(BSA-RPMI) with AS115 (0.01–10 mM) or vehicle (DMSO) at 0.1%.
After incubation for 4 hr, the cells were harvested and analyzed by
ABPP or LC-MS.
ABPP Analysis of Cancer Cell Proteomes
Cells were washed twice and scraped in ice-cold PBS. Cell pellets
were isolated by centrifugation at 1,400 3 g for 3 min and dounce-
homogenized in Tris buffer (50 mM Tris-HCl [pH 8.0]). Membrane
proteomes were isolated by centrifugation at 4C at 100,000 3 g
to provide a soluble fraction and a particulate fraction (pellet). The
pellet was washed and resuspended in Tris buffer by sonication to
provide a membrane fraction. Proteomes protein concentrations
were determined by a protein assay kit (Bio-Rad), adjusted to a final
concentration of 1 mg/ml in Tris buffer, and treated with 2 mM FP-
rhodamine for 30 min at room temperature (50 ml total reaction vol-
ume). After labeling, a portion of each sample was treated with
PNGaseF (New England Biolabs) to provide deglycosylated pro-
teomes. Reactions were quenched with one volume of standard
23 SDS/PAGE loading buffer (reducing), separated by SDS/PAGE
(10% acrylamide), and visualized in-gel with a Hitachi FMBio IIe flat-
bed fluorescence scanner (MiraiBio). Integrated band intensities
were calculated for the labeled proteins and averaged from three
independent cell samples to determine the level of each enzyme
activity. IC50 values were determined from dose-response curves
from three trials at each inhibitor concentration by using Prism soft-
ware (GraphPad) to obtain values with 95% confidence intervals.
Analysis of Cancer Cell Metabolomes
Cell pellets were harvested by scraping, isolated by centrifugation at
1,400 3 g, and dounce-homogenized in 4 ml of a 2:1:1 mixture of
chloroform:methanol:Tris buffer. Samples that were analyzed by tar-
geted LC-MS were homogenized in the presence of the following
synthetic standards: C15:0 MAG (50 pmol), C17:0 LPA (50 pmol),
and 13C-C16:0 MAGE (25 pmol). Organic and aqueous layers were
separated by centrifugation at 1,2603 g for 5 min. The organic layer
was then removed, dried under a stream of N2, and resolubilized in
100 ml chloroform, of which 30 ml was analyzed by LC-MS. Extraction
of LPA was performed by acidifying the remaining aqueous layer to
a final concentration of 5% formic acid, followed by the addition of
2 ml chloroform. The mixture was vortexed, and the organic layer
was removed, concentrated to dryness, and dissolved in 100 ml
chloroform, of which 30 ml was analyzed by LC-MS.
LC-MS analysis was performed by using an Agilent 1100 LC-MSD
SL instrument. LC separation was achieved with a Gemini reverse-
phase C18 column (5 mm, 4.6 mm 3 50 mm) from Phenomonex to-
gether with a precolumn (C18, 3.5 mm, 2 mm3 20 mm). Mobile phase
A was composed of a 95:5 ratio of water:methanol, and mobile
phase B consisted of 2-propanol, methanol, and water in a 60:35:5
ratio. Solvent modifiers such as 0.1% formic acid and 0.1% ammo-
nium hydroxide were used to assist ion formation as well as to im-
prove the LC resolution in both positive and negative ionization
modes, respectively. The flow rate for each run started at 0.1 ml/
min for 5 min, to alleviate backpressure associated with injecting
chloroform. The gradient started at 0% B and increased linearly to
100% B over the course of 40 min with a flow rate of 0.4 ml/min, fol-
lowed by an isocratic gradient of 100% B for 7 min before equilibrat-
ing for 8 min at 0% B with a flow rate of 0.5 ml/min. MS analysis was
performed with an electrospray ionization (ESI) source. The capillary
voltage was set to 3.0 kV, and the fragmentor voltage was set to
100 V. The drying gas temperature was 350C, the drying gas flow
rate was 10 L/min, and the nebulizer pressure was 35 psi. Untar-
geted data were collected by using a mass range of 200–1000 Da
and were exported as common data format (.CDF) files for com-
putational analysis. Differentially expressed metabolites between
sample pairs were identified by using the XCMS analyte profiling
software (http://metlin/download), which aligns and quantifies the
relative signal intensities of mass peaks from multiple LC-MS traces
[51]. Significant inhibitor-sensitive peak changes were confirmed bymanual quantification by using the area under the peak normalized
to total ion current. Targeted LC-MS measurements were made
by using selected ion monitoring (SIM). Peaks were quantified by
measuring the area under the peak and were normalized to an inter-
nal standard (C15:0 MAG) of endogenous lipid (palmitic acid). Abso-
lute MAGE levels were estimated by comparison to a 13C-MAGE
standard.
Preparative HPLC Purification of C16:0 MAGE
Large-scale preparations of cultured SKOV-3 cells (w4 3 107 cells)
were plated in 103 15 cm dishes and incubated in serum-free media
for 48 hr. Cells pellets were isolated as described above and homog-
enized in 8 ml of a 2:1:1 mixture of chloroform:methanol:Tris buffer.
The organic layer was removed, dried under a stream of N2, and
resolubilzed in 200 ml chloroform. The metabolite extracts were LC
purified by using a Hitachi L-7150 HPLC system equipped with a
semipreparative C18 reverse-phase column (5 mm, 10 mm 3 50
mm) from Phenomonex. Mobile phase A was composed of a 95:5 ra-
tio of water:methanol, with 0.1% formic acid, and mobile phase B
consisted of 2-propanol, methanol, and water in a 60:35:5 ratio,
with 0.1% formic acid. The gradient started at 0% B and then in-
creased linearly to 100% B over the course of 60 min, followed by
an isocratic gradient of 100% B for 20 min at a flow rate of 2.5 ml/
min. Fractions, one per minute, were collected by using a Gilson
FC 203B fraction collector. Fractions containing the 317 metabolite
were identified by MS analysis, collected, extracted with chloroform,
and concentrated to dryness, and the residue was then dissolved in
a minimal amount of solvent B (200–300 ml) for exact mass analysis.
Metabolic Labeling of Cells with 13C-2-Acetyl
MAGE and 13C-MAGE
Cells were cultured and maintained as described above. Cells used
for 13C-2-acetyl MAGE experiments were incubated in BSA-RPMI
containing inhibitor or vehicle for 30 min. BSA-RPMI medium was
then removed, supplemented with 10 mM 13C-2-acetyl MAGE or
DMSO, and reapplied to cells. After incubation for 1 hr, the cells
were harvested and metabolomes were analyzed by LC-MS. 13C-
MAGE experiments were conducted by addition of 13C-MAGE or
DMSO containing BSA-RPMI directly after washing with PBS. Cells
were then incubated for 4 hr, harvested, and analyzed by LC-MS.
Fourier Transform Mass Spectrometry, FTMS, Experiments
High-accuracy measurements were performed in the positive ion
mode by using a Bruker (Billerica, MA) APEX III (4.7 T) FTMS instru-
ment equipped with an Apollo electrospray source. The collected LC
fractions were mixed with a collection of small-molecule standards
and directly infused at 3 ml/min by using a Harvard Apparatus (Hol-
liston, MA) syringe pump. Pneumatic assist at a backing pressure
of 60 psi was used along with an optimized flow rate of heated
counter-current drying gas (300C). Ion accumulation was per-
formed by using SideKick without pulsed gas trapping. Data acqui-
sition times of approximately 1 min were used, yielding a resolving
power of w13,0000 at m/z 446 in broadband in the m/z range of
200–2,200. Calculated molecular masses for ions generated by a
mixture of small-molecule standards were used to internally cali-
brated the data.
Sulfonation of C16:0 MAGE
Endogenous HPLC-purified C16:0 MAGE or synthetic standard
(Sigma) and 1% (w/v) sulfur trioxide in 4:1 dimethylformamide and
pyridine were added to a 4 ml vial with a magnetic stir bar. This
mixture was stirred at 70C for 2 hr. The reaction mixture was then
concentrated to dryness under a stream of nitrogen, followed by
1 hr under vacuum, and the residue was then dissolved in a minimal
amount of methanol for MS/MS analysis.
Tandem MS Experiments
MS/MS experiments were performed in the negative ion mode by
using a Micromass QTof-Micro(Manchester, UK) instrument equip-
ped with a Z-spray electrospray source and a lockmass sprayer.
The source temperature was set to 110C with a cone gas flow of
150 l/hr, a desolvation gas temperature of 365C, and a nebulization
gas flow rate of 350 l/hr. The capillary voltage was set a 3.2 kV,
and the cone voltage was set at 30 V. The collision energy was set
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vard Apparatus syringe pump. MS/MS data were collected in the
centroid mode over a scan range of m/z 70–450 for acquisition times
of 2 min.
Enzyme Activity Assays with Lipid Substrates
Membrane and soluble proteomes were adjusted to 0.25 mg/ml in
Tris buffer and preincubated with AS115 (10 mM) or DMSO for 15
min. Lipid substrates (2-acetyl MAGE, 2-oleoyl MAGE, phosphati-
dylcholine, PAF) were assayed at 100 mM in 100 ml proteome at
room temperature for various amounts of time (5–40 min), after
which reactions were quenched with 200 ml chloroform and 50 ml
methanol. Lipid substrates and products were extracted into the
organic layer, concentrated to dryness, and resolubilized in 300 ml
chloroform prior to LC-MS analysis. MS settings, columns, and
mobile phases were similar to those described above. Hydrolysis
products were quantified by measuring the area under the peak in
comparison to standard curves generated with purified products.
Specific activity was determined during the linear phase of enzy-
matic reactions (i.e., less than 20% product observed). Monoacyl-
glycerol hydrolysis was measured by using a 14C-labeled 2-oleoyl-
glycerol substrate after the conversion to 14C-oleic acid by using a
thin-layer chromatography assay. For enzyme assays performed
with recombinant KIAA1363, COS7 cells were transiently trans-
fected with the human KIAA1363 cDNA in the mammalian expres-
sion vector pcDNA3 by following previously described methods [20].
Q Chromatography Enrichment of KIAA1363
Cell membranes were isolated as described above and solubilized
by rotating for 1 hr at 4C in Tris buffer containing 1% Triton X-
100. Detergent-insoluble proteins were removed by centrifugation
at 100,000 3 g for 45 min. Triton-solubilized proteomes were ad-
justed to a final protein concentration of 1 mg/ml and subjected
to anion-exchange chromatography in Tris buffer with 0.1% Triton
X-100 on a Q Sepharose HP column (Amersham Pharmacia Biotech)
with a 10 min linear gradient of 0–1 M NaCl at a flow rate of 0.5 ml/
min. Fractions were pooled, tested for 2-acetyl MAGE hydrolytic
activity, and analyzed by FP-rhodamine as described above.
Western Blotting with Anti-KIAA1363 Polyclonal Antibodies
A KIAA1363-GST fusion protein was generated by subcloning hu-
man KIAA1363 into the pGEX4T-3 fusion vector (Amersham Pharma-
cia Biotech) by using BamHI and EcoRI restriction sites. Rabbit poly-
clonal antibodies were raised against KIAA1363-GST fusion protein,
expressed in E. coli BL21 strain according to manufacturer’s recom-
mendations (Amersham Pharmacia Biotech), and administered in
conjunction with RIBI adjuvant (Corixa). Affinity purification of the
anti-KIAA1363 antibodies was conducted by first depleting rabbit
antiserum of GST-crossreactive antibodies, followed by isolation
of KIAA1363-GST reactive antibodies form the remaining serum as
previously described [52].
Preparation of a Xenograft Tumor-Derived SKOV-3 Line
In vivo-derived SKOV-3 lines were established by following previ-
ously described procedures [53]. Briefly, a well-established SKOV-
3 xenograft tumor growing in the mouse flank was removed asepti-
cally and minced with a razor blade; tumor pieces were transferred
into tissue culture flasks with complete medium. After 4 days of cul-
ture, when abundant adherent tumor cells were visible, floating
tumor debris was removed. Attached cells were then expanded to
constitute a propagatable cell population.
RNA Interference Studies in Human Cancer Cell Lines
RNA interference studies were conducted by using a variant of the
SKOV-3 line isolated by in vivo passaging in immune-deficient
mice. This in vivo-derived SKOV-3 line showed enhanced tumor-
forming capacity in vivo compared to the parental line, as has been
reported previously [54]. Short-hairpin RNA constructs were subcl-
oned into the pLP-RetroQ acceptor system, and retrovirus was
generated by using the AmphoPack-293 Cell Line (Clontech). Hairpin
oligonucleotides utilized were: for KIAA1363, 50-TGTGAACACCCC
AATCCTG-30; for DPPIV, 50-GATTCTTCTGGGACTGCTG-30. A
pLP-RetroQ vector was developed for tPa by using a validated oligo-
nucleotide sequence purchased from Clontech. Virus containingsupernatant from 24–72 hr was collected, concentrated by ultracen-
trifugation, and, in the presence of 10mg/ml polybrene, used to stably
infect SKOV-3 cells for 48 hr. Infection was followed by 3 days of se-
lection in medium containing 1 mg/ml puromycin, as the retroviral
vector contained this selection marker. Infected SKOV-3 cells were
expanded and tested for the loss of enzyme activity by ABPP.
Tumor Xenograft Studies
Human cancer xenografts were established by transplanting cancer
cell lines ectopically into the flank (SKOV-3) or mammary fat pad
(231mfp) of C.B17 SCID mice (Taconic Farms). Briefly, cells were
washed two times with PBS, trypsinized, and resuspended in me-
dium containing serum. Next, the harvested cells were washed
two times with serum-free medium and resuspended at a concentra-
tion of 4.4 3 104 cells/ml (or 1.0 3 104 cells/ml for 231mfp cells), and
100 ml was injected. Growth of the tumors was measured every 3
days with calipers.
Cell Migration Assay
Migration assays were performed in Transwell chambers with 8 mM
pore-sized membranes coated with 10 mg/ml collagen overnight at
4C (Corning). A total of 24 hr before the start of the migration assay,
cancer cell lines were plated at a concentration of 2.25 3 106 cells
per 10 cm dish. At the start of the migration assay, cells were har-
vested by washing two times with PBS and were then serum starved
in medium containing 0.05% BSA for 4 hr. Serum-starved cells were
trypsinized, spun at 1400 3 g for 3 min, resuspended, and counted.
Cells were diluted to a density of 50,000 cells/ml in medium contain-
ing 0.05% BSA, and then 250 ml was placed in the upper chamber of
the transwells. Either DMSO, C16:0-alkyl-LPA (10 nM), C16:0-alkyl-
LPC (10–1000 nM), or MAGE (10–1000 nM) in medium containing
0.05% BSA was added in the lower chamber, and cells were allowed
to migrate for 18 hr. The filters were then fixed and stained with Diff-
Quik (Dade Behring). Cells that had not migrated through the cham-
ber were removed with a cotton ball. The cells that migrated were
counted at a magnification of 403, and 6 fields were independently
counted from each migration chamber.
Cell Proliferation Assay
Cancer cell lines were plated at a concentration of 6.4 3105, 3.2 3
105, 1.6 3105, and 8 3104 cells per 10 cm dish in triplicate. They
were then counted 2, 4, 6, and 8 days after plating with trypan blue
(Sigma).
Supplemental Data
Supplemental Data include a comparison of the relative metabolite
levels in KIAA1363-inhibited versus control cancer lines, the absolute
level of MAGE lipids in SKOV-3 cells, the competitive ABPP analysis
of AS115, the structural analysis of endogenous and synthetic C16:0
MAGE, the levels of MAGE lipids in KIAA1363-inhibited and control
cancer lines, the activity of KIAA1363 with a panel of lipid substrates,
and the effect of knocking down KIAA1363 levels by shRNA on
the activity of other serine hydrolases. These data are available at
http://www.chembiol.com/cgi/content/full/13/10/1041/DC1/.
Acknowledgments
We thank S. Trauger, L. Want, G. O’Maille, and G. Siuzdak, for assis-
tance with the MS characterization of purified MAGEs; B. Mueller for
assistance with the tumor xenograft models; and members of the
Cravatt laboratory for helpful discussion and critical reading of the
manuscript. This work was supported by the National Institutes of
Health (CA087660), the California Breast Cancer Research Founda-
tion (B.F.C. and K.P.C.), the Achievement Reward for College Scien-
tists Foundation (K.P.C.), a Merck Fellowship from the Life Sciences
Research Foundation (A.S.), Burroughs Wellcome Fund Career
Award (A.S.), and the Skaggs Institute for Chemical Biology.
Received: August 5, 2006
Accepted: August 22, 2006
Published: October 20, 2006
Functional Annotation of Enzymes in Cancer
1049References
1. Patterson, S.D., and Aebersold, R. (2003). Proteomics: the first
decade and beyond. Nat. Genet. 33, 311–323.
2. Brown, P.O., and Botstein, D. (1999). Exploring the new world
of the genome with DNA microarrays. Nat. Genet. 21, 33–37.
3. Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek,
M., Mesirov, J.P., Coller, H., Loh, M.L., Downing, J.R., Caligiuri,
M.A., et al. (1999). Molecular classification of cancer: class dis-
covery and class prediction by gene expression. Science 286,
531–537.
4. Yates, J.R., III. (2004). Mass spectral analysis in proteomics.
Annu. Rev. Biophys. Biomol. Struct. 33, 297–316.
5. Domon, B., and Aebersold, R. (2006). Mass spectrometry and
protein analysis. Science 312, 212–217.
6. Evangelista, C., Lockshon, D., and Fields, S. (1996). The yeast
two-hybrid system: prospects for protein linkage maps. Trends
Cell Biol. 6, 196–199.
7. Uetz, P. (2002). Two-hybrid arrays. Curr. Opin. Chem. Biol. 6, 57–
62.
8. Jones, R.B., Gordus, A., Krall, J.A., and MacBeath, G. (2006). A
quantitative protein interaction network for the ErbB receptors
using protein microarrays. Nature 439, 168–174.
9. Gavin, A.C., Bosche, M., Krause, R., Grandi, P., Marzioch, M.,
Bauer, A., Schultz, J., Rick, J.M., Michon, A.M., Cruciat, C.M.,
et al. (2002). Functional organization of the yeast proteome by
systematic analysis of protein complexes. Nature 415, 141–147.
10. Ho, Y., Gruhler, A., Heilbut, A., Bader, G.D., Moore, L., Adams,
S.L., Millar, A., Taylor, P., Bennett, K., Boutilier, K., et al.
(2002). Systematic identification of protein complexes in
Saccharomyces cerevisiae by mass spectrometry. Nature 415,
180–183.
11. Haller, T., Buckel, T., Retey, J., and Gerlt, J.A. (2000). Discover-
ing new enzymes and metabolic pathways: conversion of succi-
nate to propionate by Escherichia coli. Biochemistry 39, 4622–
4629.
12. Vaillancourt, F.H., Yeh, E., Vosburg, D.A., O’Connor, S.E., and
Walsh, C.T. (2005). Cryptic chlorination by a non-haem iron en-
zyme during cyclopropyl amino acid biosynthesis. Nature 436,
1191–1194.
13. Kobe, B., and Kemp, B.E. (1999). Active site-directed protein
regulation. Nature 402, 373–376.
14. Remy, I., and Michnick, S.W. (2001). Visualization of biochemical
networks in living cells. Proc. Natl. Acad. Sci. USA 98, 7678–
7683.
15. Liu, Y., Patricelli, M.P., and Cravatt, B.F. (1999). Activity-based
protein profiling: the serine hydrolases. Proc. Natl. Acad. Sci.
USA 96, 14694–14699.
16. Jessani, N., and Cravatt, B.F. (2004). The development and ap-
plication of methods for activity-based protein profiling. Curr.
Opin. Chem. Biol. 8, 54–59.
17. Berger, A.B., Vitorino, P.M., and Bogyo, M. (2004). Activity-
based protein profiling: applications to biomarker discovery,
in vivo imaging and drug discovery. Am. J. Pharmacogenomics
4, 371–381.
18. Jessani, N., Liu, Y., Humphrey, M., and Cravatt, B.F. (2002). En-
zyme activity profiles of the secreted and membrane proteome
that depict cancer invasiveness. Proc. Natl. Acad. Sci. USA 99,
10335–10340.
19. Nomura, D.K., Leung, D., Chiang, K.P., Quistad, G.B., Cravatt,
B.F., and Casida, J.E. (2005). A brain detoxifying enzyme for or-
ganophosphorus nerve poisons. Proc. Natl. Acad. Sci. USA 102,
6195–6200.
20. Leung, D., Hardouin, C., Boger, D.L., and Cravatt, B.F. (2003).
Discovering potent and selective reversible inhibitors of en-
zymes in complex proteomes. Nat. Biotechnol. 21, 687–691.
21. Greenbaum, D., Baruch, A., Hayrapetian, L., Darula, Z., Burlin-
game, A., Medzihradszky, K.F., and Bogyo, M. (2002). Chemical
approaches for functionally probing the proteome. Mol. Cell.
Proteomics 1, 60–68.
22. Saghatelian, A., Trauger, S.A., Want, E.J., Hawkins, E.G., Siuz-
dak, G., and Cravatt, B.F. (2004). Assignment of endogenous
substrates to enzymes by global metabolite profiling. Biochem-
istry 43, 14332–14339.23. Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Ton-
tini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., et al.
(2003). Modulation of anxiety through blockade of anandamide
hydrolysis. Nat. Med. 9, 76–81.
24. Qian, C.G., Lee, T.C., and Snyder, F. (1989). Metabolism of plate-
let activating factor (PAF) and related ether lipids by neonatal rat
myocytes. J. Lipid Mediat. 1, 113–123.
25. Blank, M.L., Smith, Z.L., Cress, E.A., and Snyder, F. (1990). Char-
acterization of the enzymatic hydrolysis of acetate from alkyla-
cetylglycerols in the de novo pathway of PAF biosynthesis.
Biochim. Biophys. Acta 1042, 153–158.
26. Kanehisa, M., Goto, S., Kawashima, S., Okuno, Y., and Hattori,
M. (2004). The KEGG resource for deciphering the genome.
Nucleic Acids Res. 32, D277–D280.
27. Prescott, S.M., Zimmerman, G.A., Stafforini, D.M., and McIntyre,
T.M. (2000). Platelet-activating factor and related lipid media-
tors. Annu. Rev. Biochem. 69, 419–445.
28. Mills, G.B., and Moolenaar, W.H. (2003). The emerging role of
lysophosphatidic acid in cancer. Nat. Rev. Cancer 3, 582–591.
29. Xu, Y., Tanaka, M., Arai, H., Aoki, J., and Prestwich, G.D. (2004).
Alkyl lysophosphatidic acid and fluoromethylene phosphonate
analogs as metabolically-stabilized agonists for LPA receptors.
Bioorg. Med. Chem. Lett. 14, 5323–5328.
30. Jourquin, J., Yang, N., Kam, Y., Guess, C., and Quaranta, V.
(2006). Dispersal of epithelial cancer cell colonies by lysophos-
phatidic acid (LPA). J. Cell. Physiol. 206, 337–346.
31. Xiao, Y.J., Schwartz, B., Washington, M., Kennedy, A., Webster,
K., Belinson, J., and Xu, Y. (2001). Electrospray ionization mass
spectrometry analysis of lysophospholipids in human ascitic
fluids: comparison of the lysophospholipid contents in malig-
nant vs nonmalignant ascitic fluids. Anal. Biochem. 290, 302–
313.
32. Jessani, N., Young, J.A., Diaz, S.L., Patricelli, M.P., Varki, A., and
Cravatt, B.F. (2005). Class assignment of sequence-unrelated
members of enzyme superfamilies by activity-based protein
profiling. Angew. Chem. Int. Ed. Engl. 44, 2400–2403.
33. Iacobuzio-Donahue, C.A., Maitra, A., Shen-Ong, G.L., van Heek,
T., Ashfaq, R., Meyer, R., Walter, K., Berg, K., Hollingsworth,
M.A., Cameron, J.L., et al. (2002). Discovery of novel tumor
markers of pancreatic cancer using global gene expression
technology. Am. J. Pathol. 160, 1239–1249.
34. Kato, D., Boatright, K.M., Berger, A.B., Nazif, T., Blum, G., Ryan,
C., Chehade, K., Salvensen, G.S., and Bogyo, M. (2005). Activity-
based probes that target diverse cysteine protease families.
Nat. Chem. Biol. 1, 33–38.
35. Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M., and Cra-
vatt, B.F. (2004). Activity-based probes for the proteomic
profiling of metalloproteases. Proc. Natl. Acad. Sci. USA 101,
10000–10005.
36. Chan, E.W., Chattopadhaya, S., Panicker, R.C., Huang, X., and
Yao, S.Q. (2004). Developing photoactive affinity probes for
proteomic profiling: hydroxamate-based probes for metallopro-
teases. J. Am. Chem. Soc. 126, 14435–14446.
37. Sieber, S.A., Niessen, S., Hoover, H.S., and Cravatt, B.F. (2006).
Proteomic profiling of metalloprotease activities with cocktails
of active-site probes. Nat. Chem. Biol. 2, 274–281.
38. Groll, M., Nazif, T., Huber, R., and Bogyo, M. (2002). Probing
structural determinants distal to the site of hydrolysis that con-
trol substrate specificity of the 20S proteasome. Chem. Biol. 9,
655–662.
39. Li, Y.M., Xu, M., Lai, M.T., Huang, Q., Castro, J.L., DiMuzio-
Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J.G.,
et al. (2000). Photoactivated g-secretase inhibitors directed to
the active site covalently label presenilin 1. Nature 405, 689–694.
40. Vocadlo, D.J., and Bertozzi, C.R. (2004). A strategy for functional
proteomic analysis of glycosidase activity from cell lysates.
Angew. Chem. Int. Ed. Engl. 43, 5338–5342.
41. Hekmat, O., Kim, Y.W., Williams, S.J., He, S., and Withers, S.G.
(2005). Active-site peptide ‘‘fingerprinting’’ of glycosidases in
complex mixtures by mass spectrometry. Discovery of a novel
retaining b-1,4-glycanase in Cellulomonas fimi. J. Biol. Chem.
280, 35126–35135.
42. Liu, Y., Shreder, K.R., Gai, W., Corral, S., Ferris, D.K., and Rose-
nblum, J.S. (2005). Wortmannin, a widely used phosphoinositide
Chemistry & Biology
10503-kinase inhibitor, also potently inhibits mammalian polo-like
kinase. Chem. Biol. 12, 99–107.
43. Yee, M.C., Fas, S.C., Stohlmeyer, M.M., Wandless, T.J., and
Cimprich, K.A. (2005). A cell-permeable activity-based probe
for protein and lipid kinases. J. Biol. Chem. 280, 425–437.
44. Barglow, K.T., and Cravatt, B.F. (2004). Discovering disease-
associated enzymes by proteome reactivity profiling. Chem.
Biol. 11, 1523–1531.
45. Adam, G.C., Sorensen, E.J., and Cravatt, B.F. (2002). Proteomic
profiling of mechanistically distinct enzyme classes using a com-
mon chemotype. Nat. Biotechnol. 20, 805–809.
46. Speers, A.E., and Cravatt, B.F. (2005). A tandem orthogonal
proteolysis strategy for high-content chemical proteomics. J.
Am. Chem. Soc. 127, 10018–10019.
47. Kidd, D., Liu, Y., and Cravatt, B.F. (2001). Profiling serine hydro-
lase activities in complex proteomes. Biochemistry 40, 4005–
4015.
48. Patricelli, M.P., Giang, D.K., Stamp, L.M., and Burbaum, J.J.
(2001). Direct visualization of serine hydrolase activities in com-
plex proteome using fluorescent active site-directed probes.
Proteomics 1, 1067–1071.
49. Fuji, M., Watanabe, F., Fujii, Y., Hashizume, H., Okuno, T., Shir-
ahase, K., Teshirogi, I., and Ohtani, M. (1997). A stereoselective
and highly practical synthesis of cytosolic phospholipase A2
substrate, 2-S-arachidonoyl-1-O-hexadecyl-sn-2-thioglycero-
3-O-phosphocholine. J. Org. Chem. 62, 6804–6809.
50. Lamant, V., Chap, H., Klaebe, A., Perie, J., and Willson, M. (1987).
Synthesis of a thiophospho analogue of platelet activating factor
(RS)- and (S)-1-hexadecyl-2-acetylglycero-thiophosphocholine.
J. Chem. Soc. Chem. Commun. 21, 1608–1609.
51. Smith, C.A., Want, E.J., O’Maille, G., Abagyan, R., and Siuzdak,
G. (2006). XCMS: processing mass spectrometry data for me-
tabolite profiling using nonlinear peak alignment, matching,
and identification. Anal. Chem. 78, 779–787.
52. Ritter, K. (1991). Affinity purification of antibodies from sera us-
ing polyvinylidenedifluoride (PVDF) membranes as coupling ma-
trices for antigens presented by autoantibodies to triosephos-
phate isomerase. J. Immunol. Methods 137, 209–215.
53. Jessani, N., Humphrey, M., McDonald, W.H., Niessen, S., Ma-
suda, K., Gangadharan, B., Yates, J.R., III, Mueller, B.M., and
Cravatt, B.F. (2004). Carcinoma and stromal enzyme activity
profiles associated with breast tumor growth in vivo. Proc.
Natl. Acad. Sci. USA 101, 13756–13761.
54. Tanyi, J.L., Morris, A.J., Wolf, J.K., Fang, X., Hasegawa, Y.,
Lapushin, R., Auersperg, N., Sigal, Y.J., Newman, R.A., Felix,
E.A., et al. (2003). The human lipid phosphate phosphatase-3
decreases the growth, survival, and tumorigenesis of ovarian
cancer cells: validation of the lysophosphatidic acid signaling
cascade as a target for therapy in ovarian cancer. Cancer Res.
63, 1073–1082.
